Seres Therapeutics, Inc.
MCRB
$19.44
$1.126.11%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -160.75% | 309.00% | -117.61% | 370.08% | 18.10% |
| Total Depreciation and Amortization | -1.58% | -89.54% | 632.55% | -1.13% | -8.92% |
| Total Amortization of Deferred Charges | -- | -- | -100.00% | -4.54% | 4.30% |
| Total Other Non-Cash Items | -9.46% | 242.89% | 97.06% | -1,585.43% | -35.22% |
| Change in Net Operating Assets | 109.42% | 61.12% | -214.04% | 42.34% | -81.77% |
| Cash from Operations | -149.38% | 169.21% | -12.12% | 12.89% | -12.98% |
| Capital Expenditure | -432.35% | 62.22% | 30.23% | -30.30% | -59.68% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -100.00% | -- | -- |
| Other Investing Activities | -- | -- | -- | -100.00% | -- |
| Cash from Investing | -432.35% | 62.22% | -100.06% | 10,740.48% | 2,200.00% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | 100.00% | -- | -- |
| Issuance of Common Stock | -100.00% | -32.07% | -89.80% | -- | -100.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -100.00% | -32.07% | 101.57% | -- | -100.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -148.01% | 175.35% | -744.74% | 88.55% | -132.88% |